Current Report Filing (8-k)
August 28 2020 - 7:38AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): August 28,
2020
CELLULAR BIOMEDICINE GROUP, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-36498
|
|
86-1032927
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
209 Perry Parkway, Suite 13
Gaithersburg, MD
|
|
20877
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s telephone number, including area
code: (301)
825-5320
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
|
CBMG
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 Regulation FD
Disclosure.
Attached as Exhibit 99.1 to this Current Report is the form of
presentation that Cellular Biomedicine Group, Inc. intends
to use in connection with a virtual
presentation to be held at 10:10 AM Eastern Standard Time on
Sunday, August 30, 2020 at the 25th Annual Conference of the
Chinese Biopharmaceutical Association-USA. Attached as Exhibit 99.2
to this Current Report is the Press Release for the
presentation.
The foregoing (including Exhibit 99.1 and Exhibit 99.2) is being
furnished pursuant to Item 7.01 and will not be deemed to be filed
for purposes of Section 18 of the Securities and Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise be
subject to the liabilities of that section, nor will it be deemed
to be incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1
|
|
Presentation,
dated August 30, 2020
|
|
|
|
99.2
|
|
Press
Release, dated August 26, 2020
|
|
|
|
104
|
|
Cover
Page Interactive Data File (embedded within the Inline XBRL
document).
|
|
|
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
Date:
August 28, 2020
|
By:
|
/s/ Tony
(Bizuo) Liu
|
|
|
|
Tony
(Bizuo) Liu
|
|
|
|
Chief
Executive Officer
|
|
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024